Your search history is turned on.
Date: April 26, 2024 Jurisdictions: Alberta, British Columbia, Saskatchewan
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Albert Deslauriers, Chief Financial Officer of Voyageur Pharmaceuticals Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Voyageur Pharmaceutica...
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Brent Willis, President and Chief Executive Officer of Voyageur Pharmaceuticals Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Voyageur Pharm...
_ VOYAGEUR PHARMACEUTICALS LTD. MANAGEMENTS DISCUSSION & ANALYSIS FOR THE THREE MONTHS ENDED FEBRUARY 29, 2024 This managements discussion and analysis ("MD&A") presents an analysis of the consolidated financial position of Voyageur Pharmaceuticals Ltd., ("Voyageur" or the "Corporation") fo...
_ 1 VOYAGEUR PHARMACEUTICALS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED FEBRUARY 29, 2024 AND FEBRUARY 28, 2023 (Unaudited Expressed in Canadian Dollars) Notice of No Auditor Review These unaudited consolidated interim financial ...
Date: April 3, 2024 Jurisdictions: Alberta, British Columbia, Saskatchewan
Microsoft Word - news DSU April 2024 Voyageur Pharmaceuticals, Ltd. 4103 B Center Street NW Calgary, Alberta T2E 2Y6 Canada www.voyageurpharmaceuticals.ca [email protected] + 403 923 5944 Voyageur Pharmaceuticals Ltd Grants Deferred Share Units Compensation to Independent Directors Calgary, Canada The Newswire ...
Date: March 26, 2024 Jurisdictions: Alberta, British Columbia, Saskatchewan
Microsoft Word - News Release - Financial Statements and Stock Options - March 26 2024 Voyageur Pharmaceuticals, Ltd. 4103 B Center Street NW Calgary, Alberta T2E 2Y6 Canada www.voyageurpharmaceuticals.ca [email protected] + 403 923 5944 Voyageur Pharmaceuticals Files Audited Annual Financial Statements and Grants Sto...
_ VOYAGEUR PHARMACEUTICALS LTD. MANAGEMENTS DISCUSSION & ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2023 This managements discussion and analysis ("MD&A") presents an analysis of the consolidated financial position of Voyageur Pharmaceuticals Ltd., ("Voyageur" or the "Corporation") for the year ended No...
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Albert Deslauriers, Chief Financial Officer of Voyageur Pharmaceuticals Ltd., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and informat...
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Brent Willis, President and Chief Executive Officer of Voyageur Pharmaceuticals Ltd., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and...
Date: March 26, 2024 Jurisdictions: Alberta
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...